The UAE has taken a significant step forward in healthcare by becoming the second country globally to approve MIMRYLO (rusfertide), a new medication designed for adults suffering from polycythemia vera. This rare condition causes the body to overproduce red blood cells, resulting in thickened blood that poses serious risks such as dangerous clotting. Traditionally, patients have relied on therapeutic phlebotomy—a routine procedure involving the regular removal of blood—to manage their levels, but this new treatment offers a promising alternative by regulating how the body utilizes iron to keep cell production in check.

Clinical trials conducted by Takeda have shown that MIMRYLO not only effectively stabilizes red blood cell counts but also helps alleviate patient fatigue, potentially reducing the frequency of invasive blood-removal procedures. While the Emirates Drug Establishment (EDE) has hailed this as a major milestone for patients with limited treatment options, details regarding pricing, insurance coverage, and availability dates have yet to be released. Health authorities emphasize that the medication must be administered under the strict supervision of a medical professional, urging patients to maintain consistent communication with their care teams to ensure the condition is safely managed.